Standard BioTools Inc
LAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$251.28M
Close$
Share Statistics
| Market cap | $251.28 Million |
|---|---|
| Enterprise Value | $21.36 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.2 |
| Beta | 1.4 |
| Outstanding Shares | 390,881,000 |
Return
| Return on Equity | 15.72% |
|---|---|
| Return on Assets | 13.54% |
| Return on Invested Capital | -16.49% |
Valuation & Multiples
| P/E Ratio | -2.78 |
|---|---|
| PEG | 13.9 |
| Price to Sales | - |
| Price to Book Ratio | 0.64 |
| Enterprise Value to Revenue | 0.33 |
| Enterprise Value to EBIT | -0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 1.88 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$20.80 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$18.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9636▲ 29.58% |
|---|---|
| Total Calls | 22,000▼ 23.88% |
| Total Puts | 21,200▲ 9.84% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 77.89%▼ 1.42% |
|---|---|
| Total Invested | $273.37M▼ 29.43% |
| Investors Holding | 157▼ 5.00% |
ESG Score
No data
About Standard BioTools Inc
627 employees
CEO: Stephen Linthwaite Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-om...